JNTU Pharm. D IV Year PHARMACOTHERAPEUTICS - III Previous Question Paper (October - 2020 - R08)

Peptic Ulcer Disease (PUD) and Gastroesophageal Reflux Disease (GERD) are acid-related disorders managed primarily through acid suppression, mucosal protection, and eradication of Helicobacter pylori.

Pharmacotherapy of PUD:

1. H. pylori Eradication: For H. pylori-positive ulcers, a 10-14 day regimen is required. The standard triple therapy includes a Proton Pump Inhibitor (PPI) twice daily, Clarithromycin 500 mg twice daily, and Amoxicillin 1 g twice daily (or Metronidazole 500 mg if allergic to penicillin).
2. Acid Suppression: PPIs (e.g., Omeprazole, Pantoprazole) are the drugs of choice as they provide superior acid inhibition and faster ulcer healing compared to H2-receptor antagonists (H2RAs).
3. Mucosal Protective Agents: Sucralfate or Bismuth subsalicylate may be used as adjunctive therapy to coat the ulcer crater and protect against acid-pepsin damage.
4. NSAID-induced Ulcers: Discontinue the offending NSAID, initiate PPI therapy, and if NSAID continuation is mandatory, switch to a selective COX-2 inhibitor combined with a PPI.

Pharmacotherapy of GERD:

1. Lifestyle Modifications: Weight loss, elevating the head of the bed, avoiding late-night meals, and dietary triggers (caffeine, alcohol, spicy foods).
2. Antacids and Alginates: Used for rapid, short-term relief of mild, intermittent symptoms by neutralizing gastric acid.
3. H2-Receptor Antagonists (H2RAs): Agents like Famotidine are effective for mild-to-moderate GERD and can be taken on-demand or scheduled.
4. Proton Pump Inhibitors (PPIs): The gold standard for moderate-to-severe GERD and erosive esophagitis. Standard dose PPIs are typically administered once daily before the first meal for 8 weeks.
5. Prokinetic Agents: Agents like Metoclopramide may be used as add-on therapy for patients with delayed gastric emptying, though their use is limited by side effects.

Management Strategy:

Management follows a step-up or step-down approach. In GERD, start with lifestyle changes and antacids/H2RAs, escalating to PPIs if symptoms persist. In PUD, management focuses on identifying the etiology (H. pylori vs. NSAIDs), eradicating the infection, and suppressing acid to allow mucosal healing. Maintenance therapy with low-dose PPIs may be required for patients with complicated ulcers or severe erosive esophagitis.

Liver disorders encompass a spectrum of conditions ranging from acute inflammation to chronic fibrosis and cirrhosis. The etiopathology involves complex interactions between genetic predisposition, environmental triggers, and metabolic pathways.

The primary mechanisms of liver injury include:

• Hepatocellular Injury: Direct damage to hepatocytes occurs via viral infections (e.g., Hepatitis A-E), hepatotoxins (e.g., alcohol, acetaminophen, carbon tetrachloride), or immune-mediated responses. These agents induce oxidative stress, lipid peroxidation, and mitochondrial dysfunction, leading to necrosis or apoptosis.
• Cholestasis: Impairment of bile flow, either intrahepatic or extrahepatic, leads to the accumulation of bile acids within hepatocytes. This causes detergent-like injury to cell membranes and triggers inflammatory signaling pathways.
• Inflammation and Fibrogenesis: Persistent injury activates Kupffer cells (resident macrophages), which release pro-inflammatory cytokines like TNF-α and IL-1. This activates Hepatic Stellate Cells (HSCs). Once activated, HSCs transform into myofibroblast-like cells that produce excessive extracellular matrix (collagen), leading to fibrosis and eventually cirrhosis.
• Metabolic Dysregulation: Conditions like Non-Alcoholic Fatty Liver Disease (NAFLD) result from insulin resistance, leading to increased free fatty acid flux to the liver. This causes lipotoxicity, oxidative stress, and subsequent inflammation (NASH).
• Vascular Injury: Obstruction of hepatic blood flow (e.g., Budd-Chiari syndrome or congestive hepatopathy) causes ischemic injury and centrilobular necrosis due to hypoxia.

Ultimately, the progression from chronic inflammation to cirrhosis is characterized by the loss of normal hepatic architecture, the formation of regenerative nodules, and increased intrahepatic vascular resistance, which culminates in portal hypertension and hepatic failure.